Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to $2.5 million.

  • Barinthus Biotherapeutics' Other Non-Current Liabilities rose 5577.64% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 5577.64%. This contributed to the annual value of $2.6 million for FY2024, which is 4536.48% up from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Other Non-Current Liabilities is $2.5 million, which was up 5577.64% from $2.5 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' 5-year Other Non-Current Liabilities high stood at $2.8 million for Q3 2022, and its period low was $1.6 million during Q3 2024.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $2.2 million (2021), whereas its average is $2.2 million.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Other Non-Current Liabilities crashed by 3663.61% in 2023, and later soared by 5577.64% in 2025.
  • Barinthus Biotherapeutics' Other Non-Current Liabilities (Quarter) stood at $2.4 million in 2021, then dropped by 27.84% to $1.7 million in 2022, then increased by 6.55% to $1.8 million in 2023, then skyrocketed by 45.36% to $2.6 million in 2024, then decreased by 5.36% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.5 million for Q2 2025, and $2.7 million during Q1 2025.